🐴 Equine Peptide Reference
Veterinary peptide research structured for horses. 3 peptides with potential relevance to common equine conditions. All entries include explicit evidence boundaries and extra-label use disclaimers.
Common Equine Conditions with Peptide Research
BPC-157 (Veterinary)
Extensive animal studies (primarily rodents) show accelerated healing of tendons, ligaments, muscle, bone, and gastric mucosa. No published veterinary clinical trials in dogs, cats, or horses. All evidence is extrapolated from rodent models. FDA placed BPC-157 on the Category 2 compounding prohibited list in 2024. This applies to veterinary compounding as well. Obtaining BPC-157 for veterinary use may be legally and practically difficult in the US.
- •All evidence from rodent models — species translation uncertain
- •No established veterinary dosing or safety data
- •FDA Category 2 listing may prevent legal veterinary compounding in the US
- •Banned by FEI and most racing/performance organizations; competition horses may test positive
- •Should not replace standard rehabilitation protocols (rest, controlled exercise, PRP, shockwave) for tendon/ligament injuries
- •Theoretical interaction with NSAIDs commonly used in equine orthopedic and gastric ulcer management
- •May interact with NSAIDs commonly used in veterinary orthopedics
- •Should not delay or replace established standard-of-care treatments with proven efficacy
- •Document extra-label use and obtain informed consent
No established veterinary dosing exists. The doses mentioned in rodent research literature (variously reported as 10 mcg/kg/day) have not been validated in dogs, cats, or horses. Pharmacokinetics, optimal dose, route, frequency, and safety margins are unknown for veterinary species. Any dosing decision is entirely at veterinary discretion with informed owner consent.
TB-500 (Veterinary)
TB-500 (thymosin beta-4 fragment) has been studied in animal models for wound healing and angiogenesis. No published controlled trials in dogs, cats, or horses. Mechanism data from cell culture and rodent studies only.
- •No veterinary safety or efficacy data
- •Thymosin beta-4 has been investigated in cancer contexts — theoretical concern in animals with neoplasia
- •Species translation from rodent data is unvalidated
- •Should not delay or replace established standard-of-care treatments with proven efficacy
- •Document extra-label use and obtain informed consent
No established veterinary dosing. Rodent studies used varied protocols. Veterinary discretion required with informed owner consent.
LL-37 (Veterinary)
LL-37 is a human cathelicidin antimicrobial peptide with broad-spectrum activity demonstrated in vitro. Veterinary relevance is theoretical — no published clinical trials in animals. Natural cathelicidins exist in most mammals.
- •No veterinary pharmacokinetic or safety data
- •Potential for local irritation at application site
- •Antimicrobial peptides may trigger immune responses in some animals
- •Human-origin peptide may trigger antibody formation in animals; potential for reduced efficacy on repeated use and theoretical immune complex risk
- •Should not delay or replace established standard-of-care treatments with proven efficacy
- •Document extra-label use and obtain informed consent